1 – 10 of 28
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
- Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry
- Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP : Five-year follow-up of the NordCML007 study
- 2019
- Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
- 2017
- Kronisk myeloisk leukemi : förebild för målstyrd terapi - Revolutionerande överlevnadsvinster med definitiv bot i sikte och kraftigt förbättrad hälsoekonomi
- Kronisk myeloisk leukemi : Förebild för målstyrd terapi
- The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia
- Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia
- Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era - a report from the Swedish CML register
- Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34+CD38- stem and progenitor cells in chronic myeloid leukemia
-
Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML
Warfvinge, Rebecca LU ; Geironson Ulfsson, Linda LU ; Sommarin, Mikael N E LU ; Lang, Stefan LU
; Karlsson, Christine
LU
; Roschupkina, Teona
LU
; Stenke, Leif
; Stentoft, Jesper
; Olsson-Strömberg, Ulla
and Hjorth-Hansen, Henrik
, et al.
(2017)
In Blood
129(17).
p.2384-2394
Mark